The New York Community Trust   Report issue

Foundation Phase 4
Founded: New York NY United States (1924)
Status: No NME R&D (1924)

Organization Overview

First Clinical Trial
2019
NCT04152551
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

The New York Community Trust

Active Ingredients

Drugs in Phase 4 Trials (1)

risedronate (actonel) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Deafness (Phase 4)

Hearing Loss (Phase 4)

Osteogenesis Imperfecta (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 1